Adrenocortical Hyperfunction clinical trials
The registry lists 16 studies for Adrenocortical Hyperfunction across more than 10 countries. 1 are recruiting or about to start. 7 of them are mainly about Adrenocortical Hyperfunction (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 2 narrower conditions too, such as Hyperaldosteronism: 321 studies, 125 open.
Get an email when these change. Save the Adrenocortical Hyperfunction studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Novartis Pharmaceuticals (3) · Cortendo AB (1) · Neurocrine Biosciences (1) · Raffaele Antonelli Incalzi (1) · National and Kapodistrian University of Athens (1) · Shlomo Melmed, MD (1) · Corcept Therapeutics (1) · RECORDATI GROUP (1)
What is being tested here
Drugs under test in Adrenocortical Hyperfunction studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Osilodrostat | 0 | 1 | 2 |
| Hydrocortisone | 0 | 0 | 1 |
| Relacorilant | 0 | 0 | 1 |
| Levoketoconazole | 0 | 1 | 1 |
| Roscovitine | 0 | 0 | 1 |
| Pasireotide | 0 | 0 | 1 |
| Cabergoline | 0 | 0 | 1 |
| NBI 77860 | 0 | 0 | 1 |
Who these studies take
Of the 1 Adrenocortical Hyperfunction studies recruiting now, 1 (100%) set no upper age limit and 0 (0%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 1 (100%) | 1 (100%) |
| 65 | 1 (100%) | 1 (100%) |
| 75 | 1 (100%) | 1 (100%) |
| 85 | 1 (100%) | 1 (100%) |
Across all 16 studies, recruiting or not: 31% stop at 75 or younger and 19% at 65; 19% take children; 6% are for women only and 0% for men only; 31% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 11, 2026.
Studies
Recruiting first, then most recently updated. Showing 16 of 16. search them.
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)RecruitingNCT079201981 country
- Subcutaneous Hydrocortisone Children With Congenital Adrenal HyperplasiaCompletedNCT03718234Phase 11 country
- Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's DiseaseCompletedNCT0231026911 countries
- Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 11 country
- Patient and Partner Perception After Remission of Cushing's SyndromeCompletedNCT036074741 country
- A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.CompletedNCT03277690Phase 312 countries
- Treatment of Cushing's Disease With R-roscovitineTerminatedNCT02160730Phase 21 country
- Assessment of Diurnal Salivary Cortisol Production in COVID-19CompletedNCT049882691 country
- Safety and Efficacy of LCI699 in Cushing's Disease PatientsCompletedNCT01331239Phase 24 countries
- Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's DiseaseCompletedNCT02180217Phase 319 countries
- Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's DiseaseTerminatedNCT01915303Phase 216 countries
- Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Alzheimer's DiseaseCompletedNCT017077191 country
- Rhinological Outcomes in Endonasal Pituitary SurgeryCompletedNCT015043991 country
- Heart Disease Risk Factors in Major DepressionCompletedNCT000019691 country
- Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal HyperplasiaWithdrawnNCT02349503Phase 11 country
- Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal InsufficiencyCompletedNCT000011801 country